about
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on ApremilastApremilast in the treatment of psoriasis and psoriatic arthritisBedbugs: an update on recognition and management.Ingenol mebutate: an introduction.Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of ageTreatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis.Real-world experience with alitretinoin in a community dermatology practice setting in patients with chronic hand dermatitis.Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.The psychosocial impact of hidradenitis suppurativa.Review of Atopic Dermatitis and Topical Therapies.A Review of Psoriasis, Therapies, and Suicide.Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.Review of Systemic Treatment Options for Adult Atopic Dermatitis.Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.Real-World Experience With Apremilast in Treating Psoriasis.EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.Predictors of Topical Use in Psoriasis Patients in the REFINE Study.Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).Methylisothiazolinone testing at 2000 ppm: a prevalent sensitizer for allergic contact dermatitis.Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.Atopic Dermatitis, Depression, and Suicidality.Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis.Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF).Management of scalp psoriasis: current perspectives.Use of Hyaluronic Acid for Soft Tissue Augmentation of HIV-Associated Facial LipodystrophyA treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoinA soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal menImpact of a sun awareness curriculum on medical students' knowledge, attitudes, and behaviourSun and the skin: evaluation of a sun awareness program for elementary school studentsLong-term topical management of psoriasis: the road aheadAn indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsConsistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2
P50
Q26781755-6DCBA627-7A66-40B8-9F6B-008AB930085DQ26783521-25B23CE0-7B9B-4B0D-92A5-34B135DE516DQ33990363-785BF99B-5CBE-4F35-A18F-E379D5BA8A57Q34030817-78F13918-A2CD-4076-A96F-E7A027EC742BQ34982047-A3B9F6E4-E1CE-4B69-9625-48F4E5DFDE8BQ36157003-EF13888E-9390-4CFE-BC04-901DC4D91981Q37352347-9572FA88-0BDB-4933-9211-423D845D3D53Q37718001-0016DEC5-BE89-45DA-8F0A-289DEA3EB645Q38168691-4EE67DAF-E93F-45F5-9337-709AB7A81FE0Q38245960-5A2AC549-A7FB-4B63-A2E4-9180FF5A7D87Q38390436-E86C506D-8C14-4607-BD72-1A3ED9723945Q38607967-C85F9954-25BE-4BA3-8077-0A51819E6A48Q38744304-755ECEF4-0801-4283-B362-96E36266F864Q38840271-87F0569D-4769-4C85-98B2-7A8BB6AEB60DQ38843957-FEFC38D1-8E49-4E26-84BB-76A3A72BD986Q38907492-9F4B8844-9B84-48FC-86A1-9A2B64BB7EE9Q38909099-765B3A71-1019-46A3-B6B1-54F8DBF54F0CQ38956008-67F55A79-1839-4C84-B005-93E6C116C050Q38969026-9DB6CC33-EE67-4995-929D-76141ACBEEF8Q39009439-71E15A25-923E-4F93-97B8-E19E7E6D915CQ39546109-387D9B62-9DFE-4095-AD3D-863077032982Q40584386-0D228667-F704-48EA-9B52-57A26DC18CE3Q41006571-790FD249-4784-4053-B354-1E309D60E13AQ41588756-04D5ED52-9E7F-42F6-8DEB-E3E8899D2D94Q43500577-FEC965C6-A30F-4274-9828-864ECC8607BEQ47651588-FE17599E-4BA8-4C23-B8C3-780DF056894BQ47826082-0577ECCD-39FD-4510-972C-02CE5E93200FQ51637913-C29F6DF4-A497-40C4-BFE8-B5BB3920183FQ52367873-475A25F6-79AF-4FE3-B8F0-2FFED5565D37Q54402967-910DAC5F-D6E9-4C11-8C57-AE828411EDBDQ54941753-5E47C7FE-17C9-4294-B744-BACB5206D239Q56804962-F6C91981-D3E4-4DAA-A697-97B8C68B99CCQ57161979-7675C652-6168-496C-B97B-ACA489F3323DQ71402261-5B4B7D37-7043-439C-85AC-545D8D7052F8Q77873935-E5AAB05C-4EB7-4355-901D-1BBE8F170685Q77922109-7BAE9902-4418-4828-B2F9-E23A891CDED4Q89854845-B5B5A9DE-FCE6-4CD9-861E-3326A82F8E9BQ90216724-9CF592AA-E684-4265-AE78-E88DEE9A6D88Q90570257-AAC27CA0-264F-4AB5-961A-8B013C78A8B5Q90713176-52681E3C-3050-4240-BF59-2B0B512A42E1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
M Gooderham
@ast
M Gooderham
@en
M Gooderham
@es
M Gooderham
@nl
type
label
M Gooderham
@ast
M Gooderham
@en
M Gooderham
@es
M Gooderham
@nl
prefLabel
M Gooderham
@ast
M Gooderham
@en
M Gooderham
@es
M Gooderham
@nl
P106
P31
P496
0000-0001-8926-0113